These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 26245646)

  • 21. Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.
    Wagner M; Samaha D; Khoury H; O'Neil WM; Lavoie L; Bennetts L; Badgley D; Gabriel S; Berthon A; Dolan J; Kulke MH; Goetghebeur M
    Adv Ther; 2018 Jan; 35(1):81-99. PubMed ID: 29270780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Laing E; Kiss N; Michael M; Krishnasamy M
    Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
    Cives M; Strosberg J
    Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Cives M; Soares HP; Strosberg J
    Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
    Alvarado-Cabrero I; de Anda-González J; Hernández-Hernández B; Mantilla-Morales A; Valencia-Cedillo R; Medrano-Guzmán R
    Rev Gastroenterol Mex; 2012; 77(4):174-80. PubMed ID: 23142406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
    Pasricha G; Padhi P; Daboul N; Monga DK
    Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
    Mejia A; Vivian E; Nwogu C; Shah J; Longoria R; Vo A; Shahin I; Verma J; Bageac A
    Medicine (Baltimore); 2022 Mar; 101(9):e28970. PubMed ID: 35244064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
    Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.
    Gosain R; Gupta M; Roy AM; Strosberg J; Glaser KM; Iyer R
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intervention in gastro-enteropancreatic neuroendocrine tumours.
    Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
    Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
    Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Naraev BG; Mailman J; Halfdanarson TR; Soares HP; Mittra ES; Hallet J
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):601-615. PubMed ID: 37158050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.
    Tan B; Zhang B; Chen H
    Front Endocrinol (Lausanne); 2024; 15():1424839. PubMed ID: 39411312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
    Garcia-Carbonero R; Garcia-Figueiras R; Carmona-Bayonas A; Sevilla I; Teule A; Quindos M; Grande E; Capdevila J; Aller J; Arbizu J; Jimenez-Fonseca P;
    Cancer Metastasis Rev; 2015 Dec; 34(4):823-42. PubMed ID: 26433592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.